News

The proof-of-concept study will assess the efficacy and safety of sulfatinib as a monotherapy in patients with advanced BTC, whose condition has progressed on standard first-line chemotherapy, and

TRX518 is a humanized monoclonal antibody with agonist activity that has been designed to target the glucocorticord-inducible TNF-superfamily receptor (GITR). The GITR agonist has been engineered to improve

The acquisition will allow Cambrex to enter the dosage form CDMO market. Halo Pharma is majority owned by funds managed by the private investment firm SK Capital Partners.

Tibsovo, which is an oral and targeted inhibitor of the IDH1 enzyme, is said to be the first and only FDA-approved therapy for patients with R/R AML and

The primary endpoint of the trial was defined as time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3-point MACE). Tradjenta had shown similar

Under the deal, Novartis will acquire the exclusive global development and marketing rights to MOR106 for atopic dermatitis and all other potential indications. Based on the achievement of

Janssen Sciences Ireland is a subsidiary of Janssen R&D Ireland. Sylvant has approvals for the treatment of idiopathic multicentric Castleman’s disease (iMCD) in more than 40 countries such as

The study showed that patients who secured two doses of tanezumab separated by eight weeks experienced a statistically significant improvement in pain, physical function and the patients’ overall

Financial details have not been disclosed. Proleukin® is licensed in around 20 countries around the world and is primarily indicated for use in metastatic renal cell carcinoma, as